Development of combination therapies to potentiate the impact of KRAS-G12C inhibitors in lung cancer

被引：0
|
作者：
Molina-Arcas, Miriam [1 ]
Moore, Christopher [1 ]
Rana, Sareena [1 ]
Van Maldegem, Febe [1 ]
Mugarza, Edurne [1 ]
Romero-Clavijo, Pablo [1 ]
Horswell, Stuart [1 ]
Hancock, David [1 ]
Downward, Julian [1 ]
机构：
[1] Francis Crick Inst, London, England
来源：
MOLECULAR CANCER THERAPEUTICS | 2019年 / 18卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-19-B073
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B073
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
    Molina-Arcas, Miriam
    Moore, Christopher
    Rana, Sareena
    van Maldegem, Febe
    Mugarza, Edurne
    Romero-Clavijo, Pablo
    Herbert, Eleanor
    Horswell, Stuart
    Li, Lian-Sheng
    Janes, Matthew R.
    Hancock, David C.
    Downward, Julian
    SCIENCE TRANSLATIONAL MEDICINE, 2019, 11 (510)
  • [2] Combination Therapies to Maximize the Impact of KRAS-G12C Inhibitors
    Molina-Arcas, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S97 - S97
  • [3] KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies
    Naim, Nabih
    Moukheiber, Sara
    Daou, Samah
    Kourie, Hampig Raphael
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 168
  • [4] Adaptive resistance to KRAS-G12C inhibitors through AXL activation in KRAS-G12C mutant tumor cells
    Morimoto, Kenji
    Yamada, Tadaaki
    Hirai, Soichi
    Katayama, Yuki
    Yano, Seiji
    Horinaka, Mano
    Sakai, Toshiyuki
    Tokuda, Shinsaku
    Takayama, Koichi
    CANCER SCIENCE, 2024, 115 : 111 - 111
  • [5] Intracranial responses with selective KRAS-G12C inhibitors in non-small cell lung cancer
    Lu, Kevin
    Husain, Hatim
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (06) : 1335 - 1337
  • [6] KRAS-G12C in the crosshairs
    Sarah Seton-Rogers
    Nature Reviews Cancer, 2020, 20 : 3 - 3
  • [7] KRAS-G12C in the crosshairs
    Seton-Rogers, Sarah
    NATURE REVIEWS CANCER, 2020, 20 (01) : 3 - 3
  • [8] Establishment of KRAS-G12C inhibitor induced resistant tumor models enable the development of new generation KRAS-G12C inhibitors and combinatorial strategies.
    Liu, Gaoxiang
    Shi, Wenting
    Gu, Qingyang
    Ji, Qunsheng
    CANCER RESEARCH, 2021, 81 (13)
  • [9] Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer
    Yamada, T.
    Morimoto, K.
    Hirai, S.
    Katayama, Y.
    Kunimasa, K.
    Sasaki, T.
    Nishida, M.
    Watanabe, S.
    Shiotsu, S.
    Uehara, H.
    Takayama, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S194 - S194
  • [10] Repotrectinib increases effectiveness of KRAS-G12C inhibitors in KRAS-G12C mutant cancer models via simultaneous SRC/FAK/JAK2 inhibition
    Cui, J. Jean
    Zhai, Dayong
    Deng, Wei
    Rodon, Laura
    Lee, Nathan
    Murray, Brion
    CANCER RESEARCH, 2020, 80 (16)
12345